Tempus AI's $1.9 billion Personalis buy heads to a Nov 30 vote, paid in Tempus stock with up to half in cash
The $1.9 billion Personalis deal goes to a shareholder vote on November 30 with regulatory review already closed, and the filing shows Tempus pays in its own stock with up to half in cash, against $854 million on its balance sheet.
Vincent Jiangtwo-minute read
Personalis shareholders vote on November 30, 2026, on the $1.9 billion sale of their cancer-testing company to Tempus AI−6.06% — Tempus AI, down 6.06 percent today, the Chicago diagnostics and clinical-data firm, and the filing behind that vote shows exactly who writes the check 2. Regulatory review is already complete, Tempus told its Q3 earnings call on November 15 2. The consideration is Tempus stock, with up to half payable in cash at Tempus's election, decided as late as three business days before closing 3.
The maximum cash election tops the bank account
Half of the $1,920 million equity value is about $960 million in cash, against $854 million of cash and marketable securities Tempus held at September 30 2. Even the maximum cash election tops the balance sheet, and Personalis brings $213 million of its own cash, trimming the net enterprise cost to $1,709 million 3. Management told the call that operating cash flow and existing liquidity should fund both growth and the acquisition 2, but the arithmetic leaves little slack, and Tempus has burned cash in most recent quarters.
Tempus burned operating cash in eight of the last ten quarters
Data
| Operating cash flow | |
|---|---|
| Q2 '24 | -$97.08M |
| Q3 '24 | $48.66M |
| Q4 '24 | -$39.25M |
| Q1 '25 | -$105.62M |
| Q2 '25 | $44.16M |
| Q3 '25 | -$119.84M |
| Q4 '25 | -$36.79M |
| Q1 '26 | -$73.28M |
| Q2 '26 | -$7.52M |
| Q3 '26 | $9.22M |
The collar moves the price risk onto Tempus holders
Below a $48.42 floor, the exchange ratio locks at 0.3356, so Tempus issues more shares as its stock falls; Personalis can walk away below $46.00 3. Tempus traded below the lower floor on announcement day 3. Stock consideration means roughly 14.8 percent pro forma dilution 3, and a fixed $16.25 per share goes to Personalis holders either way. Tempus also pays at 15.2x EV to forward revenue, about 2.4 times the diagnostic-deal median its own bankers cited 3, and it is buying a business that loses money on every MRD test, with only 15 percent of its sales force selling the assay 2.
The $1.92 billion price is more than twice Tempus's cash pile
Even the maximum cash election tops Tempus's $854 million balance sheet
- Estimate
Data
| Value | |
|---|---|
| Tempus cash and securities, Q3 2026 | $854M |
| Max cash consideration (half of equity value) (estimate) | $960M |
| Personalis equity value | $1,920M |
Tempus's own share price now sets the price it pays
The proxy states whether Tempus elects cash, and whether the 15-day VWAP holds above $48.42 2. Tempus raised 2026 revenue guidance to about $1.60 billion with roughly $65 million of adjusted EBITDA 2, so the quarter is strong; the question is whether it can carry a money-losing target without printing shares at the bottom of a collar it wrote for itself. Deep dive in below to learn more.
Get Deals by email, free
The acquisitions, rounds and contracts that move AI money. In our daily email, every weekday.






Reader comments
0 comments